<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466271</url>
  </required_header>
  <id_info>
    <org_study_id>200611011R</org_study_id>
    <nct_id>NCT00466271</nct_id>
  </id_info>
  <brief_title>Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study</brief_title>
  <official_title>Prediction of Significant Hepatic Fibrosis in HCV Carriers With Persistently Normal Alanine Aminotransferase Levels by Splenic Arterial Pulsatility Index- A Validation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to validate the diagnostic accuracy and reproducibility of SAPI
      to predict significant hepatic fibrosis in HCV patients with PNALT who are scheduled to
      receive combination therapy with pegylated interferon plus ribavirin and percutaneous liver
      biopsies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C virus (HCV) infection is a major health problem, affecting 170 million persons
      worldwide. Approximately 25-30% of patients with chronic hepatitis C have persistently normal
      alanine aminotransferase (PNALT) levels, and another 40% have ALT levels less than twice the
      upper limit of normal (ULN). PNALT is generally defined as at least three normal ALT levels
      documented at least 2 months apart over a period of 6 months. Although the natural history of
      HCV carriers with PNALT levels remains unclear, most of them may have mild necroinflammation
      with mild or no fibrosis on liver histology, and the rate of disease progression is slower
      than patients with elevated ALT levels. However, some patients with PNALT levels still
      present with advanced fibrosis or even cirrhosis. A recent study has shown that combined
      pegylated interferon alpha plus ribavirin treatment for HCV carriers with PNALT levels can
      achieve comparable sustained virological response (SVR) to those with elevated ALT levels,
      suggesting antiviral therapy could be initiated irrespective of ALT levels. Furthermore,
      patients with initial diagnosis of significant fibrosis on liver biopsies harbor higher risks
      to advanced fibrosis and cirrhosis, and may merit antiviral therapy to stop or delay the
      progression of hepatic fibrosis.

      Currently, liver biopsy is recognized as the gold standard for assessing the grade of
      necroinflammation and stage of fibrosis before the initiation of antiviral therapy. However,
      it is costly and harbors risk of complications. In addition, sampling error due to the
      non-uniform distribution of the parenchymal damage, as well as intra- and inter-observer
      variability is often encountered. A noninvasive tool to evaluate liver disease activity or
      fibrosis stage is helpful, particularly in monitoring HCV carriers over time.

      Studies assessing the usefulness of noninvasive tests to predict hepatic fibrosis were mainly
      performed in patients with elevated ALT levels. In patients with PNALT levels, only three
      studies have addressed the value of Fibroscan, Fibro Test and aspartate aminotransferase
      (AST) to platelet ratio index (APRI). However, Fibro Test is costly and Fibroscan has not
      been widely used. In addition, APRI has not been shown by other cohorts in patients with
      PNALT levels to possess excellent diagnostic accuracy and reproducibility (32). Currently,
      splenic arterial pulsatility index (SAPI) has been shown to have superior diagnostic accuracy
      to various biochemical indices (including APRI, API (age-platelet index), and AAR (AST to ALT
      ratio)) in predicting significant hepatic fibrosis in HCV carriers with PNALT. However, SAPI
      has not been validated in an independently prospective cohort to confirm both the diagnostic
      accuracy and reproducibility. Therefore, our study is aimed to validate the diagnostic
      accuracy and reproducibility of SAPI to predict significant hepatic fibrosis in HCV patients
      with PNALT who are scheduled to receive combination therapy with pegylated interferon plus
      ribavirin and percutaneous liver biopsies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <enrollment type="Actual">102</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Hepatic Fibrosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        HCV carriers with persistently normal ALT levels who will receive percutaneous liver biopsy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age older than 18 years

          -  HCV RNA and anti-HCV positivity for more than 6 months

          -  4 consecutive normal ALT values (&lt; 40 IU/L for men and &lt; 34 IU/L for women)at 3 months
             apart over a period of 12 months

        Exclusion Criteria:

          -  HBV and HCV co-infection

          -  HBV and HIV co-infection

          -  History of heavy alcohol use (&gt; 50 gram/day)

          -  Autoimmune liver diseases

          -  Metabolic liver diseases

          -  Presence of hepatocellular carcinoma

          -  Bleeding tendency

          -  Decline liver biopsies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-Hua Liu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Internal Medicine, National Taiwan Universitys Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001 Jul 5;345(1):41-52. Review.</citation>
    <PMID>11439948</PMID>
  </reference>
  <reference>
    <citation>Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology. 2002 Nov;36(5 Suppl 1):S179-84. Review.</citation>
    <PMID>12407592</PMID>
  </reference>
  <reference>
    <citation>EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver. J Hepatol. 1999 May;30(5):956-61. Review.</citation>
    <PMID>10365827</PMID>
  </reference>
  <reference>
    <citation>Puoti C, Guido M, Mangia A, Persico M, Prati D; Committee on HCV carriers with normal alanine aminotransferase levels of the Italian Association for the Study of the Liver. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis. 2003 May;35(5):362-9.</citation>
    <PMID>12846410</PMID>
  </reference>
  <reference>
    <citation>Gholson CF, Morgan K, Catinis G, Favrot D, Taylor B, Gonzalez E, Balart L. Chronic hepatitis C with normal aminotransferase levels: a clinical histologic study. Am J Gastroenterol. 1997 Oct;92(10):1788-92.</citation>
    <PMID>9382037</PMID>
  </reference>
  <reference>
    <citation>Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, Aldegheri L, Resta S. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology. 1997 Dec;26(6):1393-8.</citation>
    <PMID>9397976</PMID>
  </reference>
  <reference>
    <citation>Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, Viladomiu L, Cheung L, DiBisceglie A, Hoofnagle J, Shih JW, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996 Jun 27;334(26):1691-6.</citation>
    <PMID>8637513</PMID>
  </reference>
  <reference>
    <citation>Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, Badalamenti S, Trépo C. Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology. 2002 Oct;36(4 Pt 1):973-7.</citation>
    <PMID>12297846</PMID>
  </reference>
  <reference>
    <citation>Alberti A, Noventa F, Benvegnù L, Boccato S, Gatta A. Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med. 2002 Dec 17;137(12):961-4.</citation>
    <PMID>12484711</PMID>
  </reference>
  <reference>
    <citation>Persico M, Persico E, Suozzo R, Conte S, De Seta M, Coppola L, Palmentieri B, Sasso FC, Torella R. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology. 2000 Apr;118(4):760-4.</citation>
    <PMID>10734027</PMID>
  </reference>
  <reference>
    <citation>Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Le Breton V, Levy S, Degott C, Valla DC, Marcellin P. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology. 2001 Nov;34(5):1000-5.</citation>
    <PMID>11679971</PMID>
  </reference>
  <reference>
    <citation>Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, Cazier A, Huraux JM, Devergie B, Vidaud M, Opolon P, Poynard T. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology. 1998 Mar;27(3):868-72.</citation>
    <PMID>9500720</PMID>
  </reference>
  <reference>
    <citation>Jamal MM, Soni A, Quinn PG, Wheeler DE, Arora S, Johnston DE. Clinical features of hepatitis C-infected patients with persistently normal alanine transaminase levels in the Southwestern United States. Hepatology. 1999 Nov;30(5):1307-11. Erratum in: Hepatology 2000 Mar;31(3):813.</citation>
    <PMID>10534355</PMID>
  </reference>
  <reference>
    <citation>Okanoue T, Makiyama A, Nakayama M, Sumida Y, Mitsuyoshi H, Nakajima T, Yasui K, Minami M, Itoh Y. A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferase. J Hepatol. 2005 Oct;43(4):599-605.</citation>
    <PMID>16024129</PMID>
  </reference>
  <reference>
    <citation>Hui CK, Belaye T, Montegrande K, Wright TL. A comparison in the progression of liver fibrosis in chronic hepatitis C between persistently normal and elevated transaminase. J Hepatol. 2003 Apr;38(4):511-7.</citation>
    <PMID>12663245</PMID>
  </reference>
  <reference>
    <citation>Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, Prati D, Shiffman M, Farci P, Gitlin N, O'Brien CB, Lamour F, Lardelli P; PEGASYS Study NR16071 Investigator Group. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology. 2004 Dec;127(6):1724-32.</citation>
    <PMID>15578510</PMID>
  </reference>
  <reference>
    <citation>Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2(2):165-73.</citation>
    <PMID>3958472</PMID>
  </reference>
  <reference>
    <citation>Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000 Sep;32(3):477-81.</citation>
    <PMID>10960438</PMID>
  </reference>
  <reference>
    <citation>McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology. 1990 Nov;99(5):1396-400.</citation>
    <PMID>2101588</PMID>
  </reference>
  <reference>
    <citation>Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986 Mar 8;1(8480):523-5.</citation>
    <PMID>2869260</PMID>
  </reference>
  <reference>
    <citation>Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003 Dec;38(6):1449-57.</citation>
    <PMID>14647056</PMID>
  </reference>
  <reference>
    <citation>Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003 Aug;39(2):239-44.</citation>
    <PMID>12873821</PMID>
  </reference>
  <reference>
    <citation>Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Ceppa P, Testa R. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003 Jan 27;163(2):218-24.</citation>
    <PMID>12546613</PMID>
  </reference>
  <reference>
    <citation>Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001 Apr 7;357(9262):1069-75.</citation>
    <PMID>11297957</PMID>
  </reference>
  <reference>
    <citation>Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat. 1997 May;4(3):199-208.</citation>
    <PMID>9181529</PMID>
  </reference>
  <reference>
    <citation>Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003 Aug;38(2):518-26.</citation>
    <PMID>12883497</PMID>
  </reference>
  <reference>
    <citation>Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005 Feb;128(2):343-50.</citation>
    <PMID>15685546</PMID>
  </reference>
  <reference>
    <citation>Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, Pirisi M. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology. 2005 Oct;42(4):838-45.</citation>
    <PMID>16121354</PMID>
  </reference>
  <reference>
    <citation>Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, Ferrari A, Alberti A. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006 Apr;44(4):686-93. Epub 2006 Feb 8.</citation>
    <PMID>16490278</PMID>
  </reference>
  <reference>
    <citation>Fabris C, Smirne C, Toniutto P, Colletta C, Rapetti R, Minisini R, Falleti E, Pirisi M. Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio index. Clin Biochem. 2006 Apr;39(4):339-43. Epub 2006 Feb 20.</citation>
    <PMID>16487951</PMID>
  </reference>
  <results_reference>
    <citation>Liu CH, Lin JW, Tsai FC, Yang PM, Lai MY, Chen JH, Kao JH, Chen DS. Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int. 2006 Nov;26(9):1087-94.</citation>
    <PMID>17032409</PMID>
  </results_reference>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2007</study_first_submitted>
  <study_first_submitted_qc>April 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>December 21, 2008</last_update_submitted>
  <last_update_submitted_qc>December 21, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>National Taiwan University Hospital</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Persistently normal alanine aminotransferase levels</keyword>
  <keyword>Hepatic fibrosis</keyword>
  <keyword>Non-invasive diagnosis</keyword>
  <keyword>Splenic arterial pulsatility index</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

